Results from a systematic review based on 9,341 patients, following an average treatment duration of 39 weeks with the more effective GLP-1 agonists, show an average monthly weight regain of 0.8kg after discontinuation of therapy.¹

In a systematic review based on 9,341 patients, a return of all cardiometabolic parameters to baseline values was predicted within 1.4 years.¹

formoline L112 EXTRA can be used both pre‑GLP‑1 as an entry therapy for overweight and post‑GLP‑1 to help counteract the yo‑yo effect.

formoline L112 EXTRA acts purely physically and locally in the gastrointestinal tract and is not absorbed into the body.⁴

Results of a double‑blind, randomised study involving 100 participants with a BMI > 30 to ≤ 35 showed a weight loss of 12.1  kg after one year of therapy with the lower‑dose preparation formoline L112 in combination with lifestyle modification.³

Within one year, waist circumference can be reduced by 13.3 cm. This is a good indicator of a reduction in visceral abdominal fat.³ This has a positive effect on metabolic syndrome.

formoline L112 is taken orally twice daily as two tablets with the main meals with the highest fat content.²

formoline L112 EXTRA is very well tolerated. The product acts purely physically and is not absorbed through the intestinal wall.²

formoline L112 EXTRA can be taken long term.⁶

Overall, 19% of men and women in Germany are affected by obesity.⁵

In Germany, 27.6% of women and 41.3% of men are overweight without obesity.⁵

Prerequisites for pharmacological therapy for weight reduction or for maintaining achieved weight loss are:⁶

• ein BMI ≥ 27 kg/m² (when using a lipase inhibitor: BMI ≥ 28) together with obesity‑associated risk factors and/or comorbidities, or
• ein BMI ≥ 30 kg/m²